Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
AbbVie
(NY:
ABBV
)
188.86
+0.29 (+0.15%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbbVie
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
68
69
Next >
Check Out 3 Health Care Stocks With Over 4% Dividend Yields From Wall Street's Most Accurate Analysts
June 26, 2023
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
1 Phenomenal High-Yield Dividend Stock You Can Buy and Hold Forever
June 25, 2023
Few high-yield dividend stocks offer all that this one does.
Via
The Motley Fool
4 Stocks That Can Turn $100,000 Into $500,000 by the Time You Retire
June 24, 2023
Buy 'em and then just get out of the way. Time and these companies' long-term strength will take care of the rest.
Via
The Motley Fool
Here's How Much $1000 Invested In AbbVie 10 Years Ago Would Be Worth Today
June 23, 2023
Via
Benzinga
Cramer Says Datadog Will 'Put Up Some Good Numbers,' And 9 More Stock Takes From 'Mad Money' Host
June 23, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Cummins (NYSE: CMI) is a buy.
Via
Benzinga
2 No-Brainer Healthcare Stocks to Buy Right Now
June 22, 2023
Don't bet against these companies.
Via
The Motley Fool
This Foreboding Sign Looms Over AbbVie's Chart
June 09, 2023
Via
Benzinga
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
June 07, 2023
Via
Benzinga
Alleged Industrial Espionage Makes an Interesting Story
June 21, 2023
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.
Via
The Motley Fool
Biotech And Healthcare Stocks Lagging
June 21, 2023
Healthcare is a laggard with XLV down YTD but UNH is still a core position.
Via
Talk Markets
RegenXbio's Potential Blockbuster: Analyst is Bullish On Stock Citing Potential Gains From AAV Gene Therapies Resurgence
June 20, 2023
Baird has initiated coverage on RegenXbio Inc (NASDAQ: RGNX) with an Outperform rating and a
Via
Benzinga
Ready for a Rebound: 7 Blue-Chips Set to Regain Their Market Mojo
June 20, 2023
Although blue-chip stocks to buy have a reputation for being slow and lumbering, these discounted ideas could swing higher.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
June 20, 2023
Via
Benzinga
Vanguard’s High Dividend Yield (VYM) ETFs Q2 Dividend – Growth
June 19, 2023
This ETF has been around for almost 20 years and boasts a very low 0.06% expense ratio.
Via
Talk Markets
Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions
June 19, 2023
An immunology drug of the Swiss pharmaceutical giant was approved for yet another indication in the European Union.
Via
The Motley Fool
Unlock the Potential of These 7 Cash-Flow Machines
June 18, 2023
Here are seven high cash flow stocks that provide investors with both growth and value under any economic conditions.
Via
InvestorPlace
This Biotech Is About to Eat AbbVie's Market Share, but Is It a Buy?
June 16, 2023
Coherus' biosimilar to Humira could catapult the company to success.
Via
The Motley Fool
AbbVie Touts Promising Results For Risankizumab For Ulcerative Colitis Maintenance
June 15, 2023
AbbVie Inc (NYSE: ABBV) announced top-line results from the COMMAND Phase 3 maintenance study, showing risankizumab (Skyrizi) achieved the primary endpoint of clinical remission at week 52, as well as...
Via
Benzinga
AbbVie vs Coherus: Dispute Emerges over Upcoming Launch of Low-Cost Biosimilar, Yusimry
June 15, 2023
AbbVie Inc (NYSE: ABBV) has challenged Coherus BioSciences Inc (NASDAQ: CHRS), alleging Coherus breached its settlement and license agreement after it announced its plans to launch Yusimry, a...
Via
Benzinga
AbbVie Says BeiGene's Flagship Blood Cancer Drug Infringes Imbruvica Patent
June 15, 2023
BeiGene Ltd (NASDAQ: BGNE) says it is aware that Pharmacyclics LLC has filed a complaint alleging that BeiGene's blood cancer therapy Brukinsa (zanubrutinib) infringes a Pharmacyclics
Via
Benzinga
AbbVie, Deere And A Major Chipmaker Set To Win In AI: CNBC's 'Final Trades'
June 13, 2023
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management said AbbVie Inc.
Via
Benzinga
Tuesday Talk: Not Clear Yet
June 13, 2023
It is not yet clear if the Fed will raise rates by a quarter point or engage in a rate hike pause, at tomorrow's FOMC meeting. The current reading on FedWatch is 79.2% pro-pause.
Via
Talk Markets
High-Yield And Attractively Valued Dividend Stocks
June 12, 2023
A look at some of the high dividend yields that are available currently, which provide both a solid income and appreciation potential.
Via
Talk Markets
Negotiation or Coercion? Big Pharma and US Chamber of Commerce Tackle Government on Drug Prices
June 12, 2023
The U.S. Chamber of Commerce has filed a lawsuit against the federal government, challenging a recent law that grants Medicare the authority to negotiate drug prices with pharmaceutical companies.
Via
Benzinga
XPeng's New EV Is a Hit, but This Biotech Stock Is Leaving It in the Dust
June 12, 2023
Find out more about two big winners Monday morning.
Via
The Motley Fool
7 Top Blue-Chip Stocks to Buy in June 2023
June 11, 2023
Investors who are looking to hold stocks through the summer should be looking for the best blue-chip stocks to buy.
Via
InvestorPlace
Better Long-Term Buy: AbbVie or Novo Nordisk?
June 10, 2023
It's important to factor in a pharmaceutical company's pipeline depth.
Via
The Motley Fool
Is AbbVie or Amgen the Better Bargain Buy Right Now?
June 08, 2023
These elite drugmakers are both working through a number of headwinds.
Via
The Motley Fool
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
June 08, 2023
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
Pharmaceutical Giant Merck Challenges Inflation Reduction Act over Medicare Drug Pricing, Calls It 'Extortion'
June 06, 2023
Merck & Co Inc (NYSE: MRK) has reportedly filed a lawsuit against the U.S. government to halt implementing the Medicare drug price negotiation program outlined in the Inflation Reduction Act (IRA).
Via
Benzinga
< Previous
1
2
...
24
25
26
27
28
29
30
31
32
...
68
69
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.